Quetiapine 50 / 200 / 300 / 400 Teva 50 mg; 200 mg; 300 mg; 400 mg FC tablets
PDF Leaflet Revision Date: 29 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of schizophrenia, bipolar disorder, and major depressive disorder.
Dosage (summary)
Adults: Start at 300 mg on Day 1, increase to 600 mg on Day 2, up to 800 mg thereafter. Elderly: Start at 50 mg, adjust as needed.
Special Populations
- Elderly
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; safety not established.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Serotonergic agents
Contraindications
- Hypersensitivity to quetiapine
- Severe hepatic impairment
- Concomitant use with CYP3A4 inhibitors
Common side effects
- Somnolence
- Dizziness
- Weight gain
- Orthostatic hypotension
Counselling Points
- Monitor for suicidal ideation
- Avoid alcohol
- Report signs of infection or agranulocytosis
Serious warnings
- Increased risk of suicidal thoughts
- Metabolic syndrome
- Tardive dyskinesia
Important Disclaimer
The Quetiapine 50 / 200 / 300 / 400 Teva 50 mg; 200 mg; 300 mg; 400 mg FC tablets professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
